Skip to content

Advertisement

  • Poster presentation
  • Open Access

Interim sample size re-estimation in the IIVOP trial

  • 1,
  • 2 and
  • 1, 3
Trials201516 (Suppl 2) :P128

https://doi.org/10.1186/1745-6215-16-S2-P128

  • Published:

Keywords

  • Public Health
  • Healthy Volunteer
  • Primary Endpoint
  • Sample Size Calculation
  • Interim Analysis

The IIVOP trial is a cross-over trial which examines the effect of the drug ivabridine in reducing pain in an enriched healthy volunteer pain model. The trial was designed based on very limited information, and as such an interim analysis was built into the design to allow the re-estimation of the sample size requirements based on updated trial parameters.

The blinded data will be used to assess the assumptions regarding the variability of the primary endpoint. If appropriate and feasible the sample size may be increased to ensure that the study is not under-powered due to incorrect assumptions. In order to control for biases, the trial will not terminate early even if the interim sample size calculations suggests that enough patients have already been enrolled to reach the desired power.

The steps of the interim sample size re-calculation, including decisions made and results, will be presented.

Authors’ Affiliations

(1)
Cambridge Clinical Trials Unit, University of Cambridge, Cambridge, UK
(2)
Division of Anaesthesia, University of Cambridge, Cambridge, UK
(3)
MRC Biostatistics Unit, Cambridge, UK

Copyright

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement